Heterologous Expression and Characterization of Indian Sahiwal Cattle (Bos indicus) Alpha Inhibin

Epitope-based in silico peptide design yields peptide-directed antibodies that recognize the buffalo luteinizing hormone

We present a novel peptide sequence identified through in silico epitope design and the later generation of peptide-directed antibodies recognizing the buffalo luteinizing hormone. Peptides and antibodies, specific to reproductive hormones, are valuable tools for developing point-of-care immunodiagnostic tools. The study predicted an epitope peptide in silico from buffalo luteinizing hormone and the generation of polyclonal antibodies against this peptide sequence. In this quest, we identified a novel epitope peptide sequence (luteinizing hormone peptide, LHP) through bioinformatics tools. The peptide was further synthesized and characterized. The polyclonal antibodies (anti-LHP) were raised against the peptide in the rabbit. Thereafter, we explored a strategy for detecting buffalo luteinizing hormone (LH) using the anti-peptide antibodies developed. The affinity of the peptide, bovine lutropin beta, and crude LH (prepared from buffalo pituitary) towards the raised antibodies was established by dot blot and ELISA. Specific recognition of the luteinizing hormone by the raised polyclonal antibodies highlights the ability of the identified peptide (LHP) and developed polyclonal antibodies (anti-LHP) as suitable diagnostic reagents for sensing the buffalo luteinizing hormone. Through this work, we analyzed and translated the "-omics" information in the LH gene sequence for the development of a novel peptide and antibodies as valuable immuno-reagents.

A proof-of-concept of lateral flow based luteinizing hormone detection in urine for ovulation prediction in buffaloes

We present a method for the detection of luteinizing hormone (LH) in buffalo urine by using gold nanoparticles (AuNPs) conjugated with novel anti-peptide antibodies against LH (anti LHP) in lateral flow assay format. Buffalo LH is an important reproductive hormone and is a chemically complex glycoprotein. Its surge release precedes ovulation and therefore detecting LH has implications in identifying the ovulation event. Any sensor thus developed for sensing LH may have the potential for predicting ovulation and hence can assist herd managers in making decisions on the timing of artificial insemination. Recombinant LH production is time consuming, difficult and costly. Hence, we identified an epitope peptide sequence in buffalo LH and raised antibodies against it. The chemically synthesized peptide and antibodies were used for developing the sensor. The gold nanoparticles and conjugates were characterized through physicochemical methods which confirmed the binding of peptides and antibodies to the gold nanoparticles. A qualitative ELISA for sensing LH was developed based on competitive binding of gold nanoparticles conjugated with the epitope peptide and LH towards the anti-peptide antibodies against LH. We also further explored the detection of LH in buffalo urine using the gold nanoparticle-LHP conjugate (AuNP-LHP) in dipstick format. These experiments provided a proof-of-concept towards applicability of the LH based sensor for ovulation prediction in buffaloes.

Trends in recombinant protein use in animal production

Recombinant technologies have made possible the production of a broad catalogue of proteins of interest, including those used for animal production. The most widely studied proteins for the animal sector are those with an important role in reproduction, feed efficiency, and health. Nowadays, mammalian cells and fungi are the preferred choice for recombinant production of hormones for reproductive purposes and fibrolytic enzymes to enhance animal performance, respectively. However, the development of low-cost products is a priority, particularly in livestock. The study of cell factories such as yeast and bacteria has notably increased in the last decades to make the new developed reproductive hormones and fibrolytic enzymes a real alternative to the marketed ones. Important efforts have also been invested to developing new recombinant strategies for prevention and therapy, including passive immunization and modulation of the immune system. This offers the possibility to reduce the use of antibiotics by controlling physiological processes and improve the efficacy of preventing infections. Thus, nowadays different recombinant fibrolytic enzymes, hormones, and therapeutic molecules with optimized properties have been successfully produced through cost-effective processes using microbial cell factories. However, despite the important achievements for reducing protein production expenses, alternative strategies to further reduce these costs are still required. In this context, it is necessary to make a giant leap towards the use of novel strategies, such as nanotechnology, that combined with recombinant technology would make recombinant molecules affordable for animal industry.